Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Human Papillomavirus | Primary research

High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study

Authors: Karim Nagi, Ishita Gupta, Nawaf Jurdi, Ayesha Jabeen, Amber Yasmeen, Gerald Batist, Semir Vranic, Ala-Eddin Al-Moustafa

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

High-risk human papillomaviruses (HPVs) are present and can cooperate with Epstein–Barr virus (EBV) to initiate and/or enhance the progression of several types of human carcinomas including cervical as well as head and neck; in parallel, it has been recently pointed out that these oncoviruses can be detected in human breast cancers. Thus, we herein explored the presence/co-presence of high-risk HPVs and EBV in breast cancer in Lebanese women.

Methods

A cohort of 102 breast cancer samples and 14 normal breast tissues were assessed for the presence of HPVs and EBV. Polymerase chain reaction (PCR) and immunohistochemistry (IHC) analysis in addition to tissue microarray (TMA) platform were used in this study.

Results

We found the presence of HPV in 66/102 (65%) of our samples, while EBV is present in 41/102 (40%) of the cohort. Additionally, our data showed that high-risk HPV types (52, 35, 58, 45, 16 and 51) are the most frequent in breast cancer in Lebanese women. Meanwhile, we report that high-risk HPVs and EBV are co-present in 30/102 (29%) of the samples; more significantly, our results indicate that their co-presence is associated with tumor grade (p = 0.03).

Conclusion

Our data revealed that HPVs and EBV are present/co-present in human breast cancer where they may play an important role in its development and/or progression; thus, we believe that further investigations are essential to confirm and elucidate the presence/co-presence of these oncoviruses and the underlying mechanisms of their interaction in breast carcinogenesis.
Literature
1.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.PubMedCrossRef
2.
Fares MY, Salhab HA, Khachfe HH, Khachfe HM. Breast cancer epidemiology among lebanese women: an 11-year analysis. Medicina (Kaunas). 2019;55(8):463.CrossRef
3.
Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56.PubMedCrossRef
4.
Lakkis NA, Adib SM, Osman MH, Musharafieh UM, Hamadeh GN. Breast cancer in Lebanon: incidence and comparison to regional and Western countries. Cancer Epidemiol. 2010;34(3):221–5.PubMedCrossRef
5.
Chouchane L, Boussen H, Sastry KS. Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol. 2013;14(10):e417-424.PubMedCrossRef
6.
Ferreira AR, Ramalho AC, Marques M, Ribeiro D. The interplay between antiviral signalling and carcinogenesis in human papillomavirus infections. Cancers. 2020;12:3.CrossRef
7.
Tulay P, Serakinci N. The route to HPV-associated neoplastic transformation: a review of the literature. Crit Rev Eukaryot Gene Expr. 2016;26(1):27–39.PubMedCrossRef
8.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550.PubMedCrossRef
9.
Bedri S, Sultan AA, Alkhalaf M, Al Moustafa A-E, Vranic S. Epstein-Barr virus (EBV) status in colorectal cancer: a mini review. Hum Vaccin Immunother. 2019;15(3):603–10.PubMedCrossRef
10.
Granados-Romero JJ, Valderrama-Treviño AI, Contreras-Flores EH, Barrera-Mera B, Herrera Enríquez M, Uriarte-Ruíz K, Ceballos-Villalba JC, Estrada-Mata AG, Alvarado Rodríguez C, Arauz-Peña G. Colorectal cancer: a review. Pathogens. 2017;5(11):10.
11.
Mehrabani-Khasraghi S, Ghane M, Ameli M. Detection of Epstein–Barr virus in colorectal cancer and Polyp by using PCR technique. Journal of Paramedical Sciences. 2014;5(4):96–101.
12.
Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng Z-M. Could human papillomaviruses be spread through blood? J Clin Microbiol. 2005;43(11):5428–34.PubMedPubMedCentralCrossRef
13.
Cyprian FS, Al-Farsi HF, Vranic S, Akhtar S, Al Moustafa A-E. Epstein–Barr virus and human papillomaviruses interactions and their roles in the initiation of epithelial–mesenchymal transition and cancer progression. Front Oncol. 2018;8:111–111.PubMedPubMedCentralCrossRef
14.
Vousden KH. Regulation of the cell cycle by viral oncoproteins. Semin Cancer Biol. 1995;6(2):109–16.PubMedCrossRef
15.
Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci USA. 1990;87(1):463–7.PubMedCrossRefPubMedCentral
16.
17.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.PubMedCrossRef
18.
Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, Howley PM. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A. 1996;93(9):4350–4.PubMedPubMedCentralCrossRef
19.
Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934–7.PubMedCrossRef
20.
Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56(20):4620–4.PubMed
21.
Dyson N, Guida P, Munger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol. 1992;66(12):6893–902.PubMedPubMedCentralCrossRef
22.
Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez P-Y, Al Moustafa A-E. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle. 2007;6(16):2038–42.PubMedCrossRef
23.
Shimakage M, Horii K, Tempaku A, Kakudo K, Shirasaka T, Sasagawa T. Association of Epstein–Barr virus with oral cancers. Hum Pathol. 2002;33(6):608–14.PubMedCrossRef
24.
Horiuchi K, Mishima K, Ichijima K, Sugimura M, Ishida T, Kirita T. Epstein–Barr virus in the proliferative diseases of squamous epithelium in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 1995;79(1):57–63.CrossRef
25.
Boudreault S, Armero VES, Scott MS, Perreault J-P, Bisaillon M. The Epstein-Barr virus EBNA1 protein modulates the alternative splicing of cellular genes. Virol J. 2019;16(1):29.PubMedPubMedCentralCrossRef
26.
Sigaroodi A, Nadji SA, Naghshvar F, Nategh R, Emami H, Velayati AA. Human papillomavirus is associated with breast cancer in the north part of Iran. Sci World J. 2012;2012:837191.CrossRef
27.
Ali SH, Al-Alwan NA, Al-Alwany SH. Detection and genotyping of human papillomavirus in breast cancer tissues from Iraqi patients. East Mediterr Health J. 2014;20(6):372–7.PubMedCrossRef
28.
Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, Turhal NS. HPV DNA frequency and subset analysis in human breast cancer patients’ normal and tumoral tissue samples. J Exp Clin Cancer Res. 2006;25(4):515–21.PubMed
29.
Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer. 2008;99(3):404–7.PubMedPubMedCentralCrossRef
30.
Brumbaugh J, Ferris RL, Hu S. HPV and EBV in Head and Neck Cancer. In: Bernier J, editor. Head and neck cancer: multimodality management. Cham: Springer; 2016. p. 163–79.CrossRef
31.
Malki MI, Gupta I, Fernandes Q, Aboulkassim T, Yasmeen A, Vranic S, Al Moustafa AE, Al-Thawadi HA. Co-presence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian colorectal cancer samples. Hum Vaccin Immunother. 2020;16(10):2403–7.PubMedPubMedCentralCrossRef
32.
Al-Thawadi H, Gupta I, Jabeen A, Skenderi F, Aboulkassim T, Yasmeen A, Malki MI, Batist G, Vranic S, Al Moustafa A-E. Co-presence of human papillomaviruses and Epstein–Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients. Cancer Cell Int. 2020;20:361.PubMedPubMedCentralCrossRef
33.
Al-Thawadi H, Ghabreau L, Aboulkassim T, Yasmeen A, Vranic S, Batist G, Al Moustafa A-E. Co-incidence of Epstein–Barr virus and high-risk human papillomaviruses in cervical cancer of syrian women. Front Oncol. 2018;8:250–250.PubMedPubMedCentralCrossRef
34.
Al Moustafa A-E, Al-Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A. Co-prevalence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. Hum Vaccin Immunother. 2016;12(7):1936–9.PubMedPubMedCentral
35.
Gupta I, Jabeen A, Al-Sarraf R, Farghaly H, Vranic S, Sulta AA, Al Moustafa A-E, Al-Thawadi H. The co-presence of high-risk human papillomaviruses and Epstein–Barr virus is linked with tumor grade and stage in Qatari women with breast cancer. Hum Vaccin Immunother. 2020;17(3):1–8.
36.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.PubMedCrossRef
37.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66.PubMedCrossRef
38.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364–82.PubMedCrossRef
39.
Gupta I, Nasrallah GK, Sharma A, Jabeen A, Smatti MK, Al-Thawadi HA, Sultan AA, Alkhalaf M, Vranic S. Moustafa A-EA: Co-prevalence of human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) in healthy blood donors from diverse nationalities in Qatar. Cancer Cell Int. 2020;20:107–107.PubMedPubMedCentralCrossRef
40.
Gupta I, Al Farsi H, Jabeen A, Skenderi F, Al-Thawadi H, AlAhmad YM, Abdelhafez I, Al Moustafa A-E, Vranic S. High-risk human papillomaviruses and Epstein–Barr virus in colorectal cancer and their association with clinicopathological status. Pathogens. 2020;9(6):452.PubMedCentralCrossRef
41.
Heng B, Glenn WK, Ye Y, Tran B, Delprado W, Lutze-Mann L, Whitaker NJ, Lawson JS. Human papilloma virus is associated with breast cancer. Br J Cancer. 2009;101(8):1345–50.PubMedPubMedCentralCrossRef
42.
Xiao C-Y, Fu B-B, Li Z-Y, Mushtaq G, Kamal MA, Li J-H, Tang G-C, Xiao S-S. Observations on the expression of human papillomavirus major capsid protein in HeLa cells. Cancer Cell Int. 2015;15:53–53.PubMedPubMedCentralCrossRef
43.
Al Moustafa A, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene. 2004;23:350–8.PubMedCrossRef
44.
Khodabandehlou N, Mostafaei S, Etemadi A, Ghasemi A, Payandeh M, Hadifar S, Norooznezhad AH, Kazemnejad A, Moghoofei M. Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins. BMC Cancer. 2019;19(1):61.PubMedPubMedCentralCrossRef
45.
Herrera-Goepfert R, Vela-Chávez T, Carrillo-García A, Lizano-Soberón M, Amador-Molina A, Oñate-Ocaña LF. Hallmann RS-R: High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women. BMC Cancer. 2013;13(1):445.PubMedPubMedCentralCrossRef
46.
Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, Higashi M, Sagara Y, Yoshinaka H, Tsuji T, et al. Human papillomavirus detected in female breast carcinomas in Japan. Br J Cancer. 2008;99(3):408–14.PubMedPubMedCentralCrossRef
47.
Fernandes A, Bianchi G, Feltri AP, Pérez M, Correnti M. Presence of human papillomavirus in breast cancer and its association with prognostic factors. Ecancermedicalscience. 2015;9:548.PubMedPubMedCentralCrossRef
48.
Maroun CA, Al Feghali K, Traboulsi H, Dabbous H, Abbas F, Dunya G, Ziade G, Mahfouz R, Youssef B, Tamim H, et al. HPV-related oropharyngeal cancer prevalence in a middle eastern population using E6/E7 PCR. Infect Agent Cancer. 2020;15(1):1.PubMedPubMedCentralCrossRef
49.
Mroueh AM, Seoud MA, Kaspar HG, Zalloua PA. Prevalence of genital human papillomavirus among Lebanese women. Eur J Gynaecol Oncol. 2002;23(5):429–32.PubMed
50.
Moosa K, Alsayyad AS, Quint W, Gopala K, DeAntonio R. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014;14:905–905.PubMedPubMedCentralCrossRef
51.
Al-Lawati Z, Khamis FA, Al-Hamdani A, Al-Kalbani M, Ramadhan FA, Al-Rawahi TR, Al-Kobaisi MF. Prevalence of human papilloma virus in Oman: Genotypes 82 and 68 are dominating. Int J Infect Dis. 2020;93:22–7.PubMedCrossRef
52.
Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, Irie Y, Takahashi E, Tanigami A, Izumi K. Human papillomavirus type 33 dna in breast cancer in Chinese. Breast Cancer. 2000;7(1):33–6.PubMedCrossRef
53.
Lawson JS, Glenn WK, Salyakina D, Delprado W, Clay R, Antonsson A, Heng B, Miyauchi S, Tran DD, Ngan CC, et al. Human papilloma viruses and breast cancer. Front Oncol. 2015;5:277–277.PubMedPubMedCentralCrossRef
54.
Wang T, Chang P, Wang L, Yao Q, Guo W, Chen J, Yan T, Cao C. The role of human papillomavirus infection in breast cancer. Med Oncol. 2012;29(1):48–55.PubMedCrossRef
55.
Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, Lawson JS. Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS ONE. 2012;7(11):e48788–e48788.PubMedPubMedCentralCrossRef
56.
Joshi D, Quadri M, Gangane N, Joshi R, Gangane N. Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. PLoS ONE. 2009;4(12):e8180–e8180.PubMedPubMedCentralCrossRef
57.
Lorenzetti MA, De Matteo E, Gass H, Martinez Vazquez P, Lara J, Gonzalez P, Preciado MV, Chabay PA. Characterization of Epstein–Barr virus latency pattern in Argentine breast carcinoma. PLoS ONE. 2010;5(10):e13603–e13603.PubMedPubMedCentralCrossRef
58.
Fawzy S, Sallam M, Awad NM. Detection of Epstein–Barr virus in breast carcinoma in Egyptian women. Clin Biochem. 2008;41(7–8):486–92.PubMedCrossRef
59.
Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE. Epstein–Barr virus gene expression in human breast cancer: protagonist or passenger? Br J Cancer. 2003;89(1):113–9.PubMedPubMedCentralCrossRef
60.
Kalkan A, Ozdarendeli A, Bulut Y, Yekeler H, Cobanoglu B, Doymaz MZ. Investigation of Epstein–Barr virus DNA in formalin-fixed and paraffin- embedded breast cancer tissues. Med Princ Pract. 2005;14(4):268–71.PubMedCrossRef
61.
Aboulkassim T, Yasmeen A, Akil N, Batist G, Al Moustafa A-E. Incidence of Epstein–Barr virus in Syrian women with breast cancer: A tissue microarray study. Hum Vaccin Immunother. 2015;11(4):951–5.PubMedPubMedCentralCrossRef
62.
Zekri ARN, Bahnassy AA, Mohamed WS, El-Kassem FA, El-Khalidi SJ, Hafez MM, Hassan ZK. Epstein–Barr virus and breast cancer: epidemiological and Molecular study on Egyptian and Iraqi women. J Egypt Natl Cancer Inst. 2012;24(3):123–31.CrossRef
63.
Hachana M, Amara K, Ziadi S, Romdhane E, Gacem RB, Trimeche M. Investigation of Epstein-Barr virus in breast carcinomas in Tunisia. Pathol Res Pract. 2011;207(11):695–700.PubMedCrossRef
64.
Sharifpour C, Makvandi M, Samarbafzadeh A, Talaei-Zadeh A, Ranjbari N, Nisi N, Azaran A, Jalilian S, Varnaseri M, Pirmoradi R, et al. Frequency of Epstein–Barr virus DNA in formalin-fixed paraffin-embedded tissue of patients with ductal breast carcinoma. Asian Pac J Cancer Prev. 2019;20(3):687–92.PubMedPubMedCentralCrossRef
65.
Farahmand M, Monavari SH, Shoja Z, Ghaffari H, Tavakoli M, Tavakoli A. Epstein–Barr virus and risk of breast cancer: a systematic review and meta-analysis. Future Oncol. 2019;15(24):2873–85.PubMedCrossRef
66.
Hu H, Luo M-L, Desmedt C, Nabavi S, Yadegarynia S, Hong A, Konstantinopoulos PA, Gabrielson E, Hines-Boykin R, Pihan G, et al. Epstein–Barr virus infection of mammary epithelial cells promotes malignant transformation. EBioMedicine. 2016;9:148–60.PubMedPubMedCentralCrossRef
67.
Al Moustafa A-E, Chen D, Ghabreau L, Akil N. Association between human papillomavirus and Epstein–Barr virus infections in human oral carcinogenesis. Med Hypotheses. 2009;73(2):184–6.PubMedCrossRef
68.
Lawson JS, Glenn WK. Multiple oncogenic viruses are present in human breast tissues before development of virus associated breast cancer. Infect Agent Cancer. 2017;12(1):55.PubMedPubMedCentralCrossRef
69.
Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer. 2014;50(10):1808–18.PubMedCrossRef
70.
Lawson JS, Salmons B, Glenn WK. Oncogenic viruses and breast cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein–Barr Virus (EBV). Front Oncol. 2018;8:1–1.PubMedPubMedCentralCrossRef
71.
Aguayo F, Khan N, Koriyama C, González C, Ampuero S, Padilla O, Solís L, Eizuru Y, Corvalán A, Akiba S. Human papillomavirus and Epstein-Barr virus infections in breast cancer from chile. Infect Agents Cancer. 2011;6(1):7–7.CrossRef
72.
Naushad W, Surriya O, Sadia H. Prevalence of EBV, HPV and MMTV in Pakistani breast cancer patients: a possible etiological role of viruses in breast cancer. Infect Genet Evol. 2017;54:230–7.PubMedCrossRef
73.
Gupta I, Jabeen A, Vranic S, Al Moustafa A-E, Al-Thawadi H. Oncoproteins of high-risk HPV and EBV cooperate to enhance cell motility and invasion of human breast cancer cells via Erk1/Erk2 and β-catenin signaling pathways. Front Oncol. 2021;11:515.CrossRef
Metadata
Title
High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study
Authors
Karim Nagi
Ishita Gupta
Nawaf Jurdi
Ayesha Jabeen
Amber Yasmeen
Gerald Batist
Semir Vranic
Ala-Eddin Al-Moustafa
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02009-4

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors

Primary research

Regulator of cullins-1 (ROC1) negatively regulates the Gli2 regulator SUFU to activate the hedgehog pathway in bladder cancer

Primary Research

Prodigiosin inhibits cholangiocarcinoma cell proliferation and induces apoptosis via suppressing SNAREs-dependent autophagy

Primary research

Engineered exosomes loaded with miR-449a selectively inhibit the growth of homologous non-small cell lung cancer

Primary research

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib

Correction

Correction to: The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits